Sortino ratio is not yet available for CNCR. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.
How it compares to other similar ETFs
The table compares Loncar Cancer Immunotherapy ETF's Sortino Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how CNCR's risk-adjusted performance compares to similar funds.
Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jun 3, 2026.
| Symbol | Name | 1Y Sortino Ratio | 5Y Sortino Ratio | 10Y Sortino Ratio | All Time Sortino Ratio |
|---|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 4.11 | |||
| IHE | iShares U.S. Pharmaceuticals ETF | 3.33 | |||
| LFSC | F/m Emerald Life Sciences Innovation ETF | 3.25 | |||
| SBIO | ALPS Medical Breakthroughs ETF | 3.17 | |||
| XBI | SPDR S&P Biotech ETF | 3.14 | |||
| CANC | Tema Oncology ETF | 3.05 | |||
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 3.02 | |||
| IBRN | iShares Neuroscience and Healthcare ETF | 2.94 | |||
| PJP | Invesco Dynamic Pharmaceuticals ETF | 2.91 | |||
| GNOM | Global X Genomics & Biotechnology ETF | 2.89 | |||
| CNCR | Loncar Cancer Immunotherapy ETF | — |
Historical Sortino Ratio
The chart shows CNCR's rolling Sortino ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to downside risk, while declining trends may signal deteriorating risk-adjusted performance or increased volatility during market stress. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when CNCR consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading charts...
IHow does CNCR fit in your portfolio?
Add your other holdings to see your portfolio's Sortino Ratio and find out.
Analyze Your Portfolio